Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Compounds for Treatin...
Routine Notice Added Final

USPTO Patent Application: Compounds for Treating Parasitic Protozoa Infections

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260083728A1) detailing compounds for treating infections caused by parasitic protozoa, specifically Leishmania or Trypanosoma. The application was filed on September 18, 2023, by inventors from Karl WERBOVETZ et al.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083728A1) for compounds and pharmaceutical compositions useful in treating infections caused by parasitic protozoa, such as Leishmania or Trypanosoma. The application describes compounds of Formula I and Formula II and their pharmaceutically acceptable salts or derivatives. The filing date was September 18, 2023.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in treatments for parasitic protozoal infections, which may be of interest to pharmaceutical companies and researchers in the field. No immediate actions or deadlines are associated with this publication.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOUNDS FOR TREATING INFECTIONS WITH PARASITIC PROTOZOA

Application US20260083728A1 Kind: A1 Mar 26, 2026

Inventors

Karl WERBOVETZ, Pankaj SHARMA, Chris LA ROSA, Zhuo WANG, Yiru JIN, Mei FENG

Abstract

This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular protozoa of the genera Leishmania or Trypanosoma.

CPC Classifications

A61K 31/496 A61P 33/02 C07D 207/325 C07D 213/36 C07D 231/12 C07D 233/61 C07D 249/08 C07D 295/192

Filing Date

2023-09-18

Application No.

19111246

View original document →

Named provisions

Abstract Inventors

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 18th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083728A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Discovery Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
R&D
Compliance frameworks
GxP
Topics
Drug Development Infectious Diseases

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!